Pirtobrutinib for Relapsed CLL After Covalent BTKi Therapy

1 Views

Thanks! Share it with your friends!

You disliked this video. Thanks for the feedback!

Published Apr 21, 2025

Chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL / SLL) can develop resistance mutations to covalent BTK inhibitor (BTKi) drugs over time. Pirtobrutinib is a noncovalent BTKi that binds in a reversible manner and can overcome covalent BTKi resistance mutations. This study compared the efficacy of pirtobrutinib vs. investigators’ choice of either idelalisib plus rituximab or bendamustine plus rituximab in patients with CLL / SLL previously treated with a covalent BTKi.

Pirtobrutinib provides longer progression-free survival and is safer than idelalisib–rituximab and bendamustine-rituximab for treating relapsed CLL.

Dr. Jeff Sharman from Willamette Valley Cancer Institute and Research Center and colleagues presented the results at the American Society for Hematology (ASH) Annual Meeting 2024.

Read the full article on CLL Society's website at: https://cllsociety.org/2025/04/pirtobrutinib-for-relapsed-cll-after-covalent-btki-therapy/
__________________________________________________________________________________________
CLL Society Website: https://cllsociety.org/
Facebook: https://www.facebook.com/CLLsociety
Twitter: https://twitter.com/CllSociety
LinkedIn: https://www.linkedin.com/company/cll-society/